抗体-药物结合物（ADC）由理想的单克隆抗体、活性细胞毒性药物和合适的连接剂组成。抗体和细胞毒性药物之间的适当连接物提供特异性桥，从而帮助抗体选择性地将细胞毒性药物递送至肿瘤细胞，并在肿瘤部位精确地释放细胞毒性药物
2,5-Dioxopyrrolidin-1-yl 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19-pentaoxa-4-azadocosan-22-oate
3,6,9,12,15,18,21,24,27,30-Decaoxadotriacontane-1,32-diol
1-Phenyl-2,5,8,11,14,17-hexaoxanonadecan-19-ol
1-Phenyl-2,5,8,11,14,17,20-heptaoxadocosan-22-ol
1-Phenyl-2,5,8,11,14,17,20,23-octaoxapentacosan-25-ol
1-Phenyl-2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-ol
1-Phenyl-2,5,8,11,14,17,20,23,26,29-decaoxahentriacontan-31-ol
2,5,8,11,14,17,20,23,26,29-Decaoxahentriacontan-31-ol
1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid
1-(17-Hydroxy-3,6,9,12,15-pentaoxaheptadecyl)-1H-pyrrole-2,5-dione
2,5-Dioxopyrrolidin-1-yl 1-chloro-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oate
3,6,9,12,15-Pentaoxatricosan-1-ol
3,6,9,12,15,18,21,24-Octaoxahexacosane-1,26-diol
3,6,9,12,15,18,21-Heptaoxatricosane-1,23-diol
Pentaethylene glycol di-p-toluenesulfonate
2-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethyl acrylate
5,8,11-Trioxa-2-azatridecan-13-ol
Poly(ethylene glycol) dimethyl ether Mn 250
2,5,8,11-Tetraoxatridecane-13-thiol
3,6,9,12,15,18,21,24-Octaoxahexatriacontan-1-ol
13-Azido-2,5,8,11-tetraoxatridecane
2-(2-(2-(2-(4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethanol dihydrochloride
2,5-Dioxopyrrolidin-1-yl 3-(2-(2-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)ethoxy)ethoxy)propanoate
Sodium 1-((4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carbonyl)oxy)-2,5-dioxopyrrolidine-3-sulfonate
Bis(perfluorophenyl) 4,7,10,13-tetraoxahexadecane-1,16-dioate
Di-tert-butyl 4,7,10,13,16-pentaoxanonadecane-1,19-dioate
3,6,9,12,15,18,21,24,27-Nonaoxanonatriacontan-1-ol
2,2,3,3-Tetramethyl-4,7,10-trioxa-3-siladodecan-12-ol
3-Oxo-1-phenyl-2,7,10,13,16-pentaoxa-4-azaoctadecan-18-oic acid
